Samoemulzirajući pripravci za peroralnu primjenu simvastatina: Ispitivanja in vitro i in vivo by Pradeep Patil et al.
For the therapeutic delivery of lipophilic active moieties (Class II drugs), lipid based
formulations are inviting increasing attention. Amongst many such delivery options, like
incorporation of drug in oils (1), surfactant dispersions (2), emulsions (3) and liposomes
(4), one of the most popular approaches are the self-emulsifying drug delivery systems
(SEDDS). SEDDS are mixtures of oils and surfactants, ideally isotropic, and sometimes
containing cosolvents, which emulsify spontaneously to produce fine oil-in-water emul-
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The objective of the present work was to formulate a
self-emulsifying drug delivery system (SEDDS) for sim-
vastatin, which is widely used in the treatment of hyper-
cholesterolemia and dyslipidemia as an adjunct to diet.
Simvastatin SEDDS were formulated using a 1:1 (V/V)
mixture of diesters of caprylic/capric acids and polygly-
colyzed glycerides with varying concentrations of poly-
oxy castor oil and C8/C10 mono-/diglycerides. The de-
veloped SEDDS were evaluated for turbidimetry, droplet
size analysis, drug content and in vitro diffusion profiles.
In vivo performance of the optimized formulation was
evaluated in rats using pharmacodynamic marker para-
meters like plasma total cholesterol (CH), triglycerides
(TG) and high-density lipoprotein (HDL-CH) for 21 days.
SEDDS containing 9.1% (m/m) simvastatin and 23.0% (m/m)
of each excipient showed minimum mean droplet size
(124 nm) and optimal drug diffusion. This test formula-
tion showed significant reduction in plasma CH and TG
(around 5-fold and 4-fold, respectively), while HDL-CH
concentration was markedly higher (2-fold) compared a
reference simvastatin suspension formulation after oral
administration for 21 days of study. Test formulation has
shown enhanced pharmacodynamic performance compar-
ed to reference formulation in rats. The study illustrated
the potential of simvastatin SEDDS for oral administra-
tion and its biopharmaceutic performance.
Keywords: simvastatin, SEDDS, pharmacodynamics, oral
administration, plasma lipids
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sions when introduced into aqueous phase under gentle agitation (5). Upon peroral ad-
ministration, these systems form fine oil-in-water emulsions (or microemulsions) in the
gastro-intestinal (GI) tract with mild agitation provided by gastric mobility. These sys-
tems advantageously present the drug in dissolved form and the small droplet size pro-
vides a large interfacial area for drug absorption (6, 7). Many researchers have reported
various rational applications of SEDDS for delivering and targeting lipophilic drugs,
e.g., coenzyme Q10 (8), vitamin E (9), halofantrine (10) and cyclosporin A (11). Potential
advantages of these systems include enhanced oral bioavailability (enabling dose reduc-
tion), more consistent temporal profiles of drug absorption, selective drug targeting to-
ward a specific absorption window in the GI tract, and drug protection from the hostile
environment in the gut (12, 13). For selecting a suitable self-emulsifying vehicle, drug
solubility in various components, identification of emulsifying regions and resultant droplet
size distribution need careful monitoring, since these are drug-specific systems (8).
Simvastatin, a crystalline compound, is practically insoluble in water and hence po-
orly absorbed from the GI tract (14). It is a potent and specific inhibitor of 3-hydroxy-
-3-methyl-glutaryl coenzyme A (HMG CoA) reductase, which catalyzes the reduction of
HMG CoA to mevalonate. Thus, simvastatin arrests a key step for cholesterol biosyn-
thesis in liver, and is hence widely used in the treatment of hypercholesterolemia and
dyslipidemia, as an adjunct to diet. After oral administration, simvastatin is metabolized
to its b-dihydroxy acid form (simvastatin acid) by the cytochrome-3A system in liver,
where it inhibits the rate-limiting step in cholesterol biosynthesis (15, 16). This leads to
up-regulation of low-density lipoprotein (LDL) receptors and an increase in catabolism
of LDL cholesterol. There may also be some reduction in LDL production as a result of
inhibition of hepatic synthesis of very low-density lipoprotein (VLDL), the precursor of
LDL (17). Being a Class II drug, it often shows dissolution rate-limited oral absorption
and high variability in pharmacological effects. Therefore, improvements in its solubility
and/or dissolution rate may lead to enhancement in bioavailability. Various attempts to
enhance the dissolution rate and bioavailability of simvastatin have been reported (14, 18).
In the present study, SEDDS formulations containing simvastatin were developed
using different proportions of oils and surfactant systems for oral administration. Isotro-
pic systems were evaluated for the quality of emulsion produced, mean droplet size and
in vitro drug diffusion. Optimized formulation was further evaluated for its in vivo per-
formance in albino rats using pharmacodynamic markers such as plasma levels of total
cholesterol (CH), high-density lipoprotein cholesterol (HDL-CH), triglycerides (TG), low-
-density lipoproteins (LDL) and very low-density lipoproteins (VLDL). Pharmacodynamic
performance of the developed (test) formulation was compared against a reference for-
mulation and was further analyzed statistically.
EXPERIMENTAL
Materials
Simvastatin was a generous gift from Ivax India Pvt. Ltd. (India). Diesters of cap-
rylic/capric acids (Captex® 355) and C8/C10 mono-/diglycerides (Capmul® MCM) were
generous gifts from Abitec Corp (USA). Polyglycolyzed glyceride (Lauroglycol® 90) was
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a gift sample provided by Gattefosse (France). Polyoxyl 35 castor oil (Cremophore® EL,
Cr-EL) was purchased from BASF (Germany). In vitro diagnostic kits (Cholesterol LS,
HDL-CH and Triglycerides) were purchased from Ensure Biotech, India. Sigma® Dialysis
Tubing (seamless cellulose tubing, MWCO 12000) was purchased from Sigma Chemical
Co., USA. All other chemicals and reagents were of analytical grade and used as received.
Preliminary studies
Apparent solubilities of simvastatin were determined in different oils at ambient
temperature. Based on these results, the oils selected were formulated in SEDDS using
different surfactant systems (with varying ratios of surfactant to cosurfactant) by mixing
the components in sealed glass vials. These systems were titrated with water and phase
clarity and quality of emulsion produced were visually observed.
Formulation of SEDDS
Various formulations were prepared with a constant amount of simvastatin (9.09%,
m/m) and varying ratios of surfactant to cosurfactant (Table I). In brief, simvastatin was
dissolved in 1:1 (V/V) mixture of Captex and Lauroglycol (used as oil phase) in stop-
pered glass vials. Required amounts of Cr-EL and/or Capmul were added to the mix-
ture and mixed well. These systems were warmed to 40 °C using a water bath for 30 min
with intermittent shaking to ensure complete mixing. The prepared formulations were
stored at ambient conditions until further use.
Turbidimetric evaluation
Self-emulsifying system (0.2 mL) was added to 0.1 mol L–1 hydrochloric acid (150
mL) under continuous stirring (50 rpm) on a magnetic plate (Ika-Werke, Germany) at
ambient temperature, and the increase in turbidity was measured untill equilibrium was
achieved using a turbidimeter (Type 131, Systronics, India). However, since the time re-
quired for complete emulsification was too short, it was not possible to monitor the rate
of change of turbidity (rate of emulsification).
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Table I. Compositions of SEDDS formulations
Composition
Formulation
A B Ca D E
Simvastatin (mg) 200 200 200 200 200
Captex 355 (mL) 0.5 0.5 0.5 0.5 0.5
Lauroglycol 90 (mL) 0.5 0.5 0.5 0.5 0.5
Cremophor EL (mL) 1.0 0.75 0.5 0.25 –
Capmul MCM (mL) – 0.25 0.5 0.75 1.0
a Test formulation
Droplet size analysis
Droplet size distribution of SEDDS diluted with water was determined using a pho-
ton correlation spectrometer (Zetasizer 3000 HAS, Malvern Ltd., UK) based on the laser
light scattering phenomenon. Samples were diluted 200 times with purified water. Di-
luted samples were directly placed into the module and measurements were made in
triplicate after 2-min stirring. Droplet size was calculated from the volume size distribu-
tion.
Drug content
Simvastatin from preweighed SEDDS was extracted by dissolving in 25 mL metha-
nol. Simvastatin content in the methanolic extract was analyzed spectrophotometrically
(Jasco V-530, Japan) at 238 nm, against the standard methanolic solution of simvastatin.
In vitro drug diffusion studies
In vitro diffusion studies were carried out for formulations A, B and C using the di-
alysis technique. One end of pretreated cellulose dialysis tubing (7 cm in length) was
tied with thread and then 0.2 mL of self-emulsifying formulation (equivalent to 10 mg
simvastatin) was placed in it along with 0.8 mL of dialyzing medium. The other end of
tubing was also secured with thread and was allowed to rotate freely in the dissolution
vessel of a USP 24 type II dissolution test apparatus (Electrolab TDT-06P, India) that con-
tained 900 mL dialyzing medium (phosphate buffer pH 6.8) maintained at 37 ± 0.5 °C
and stirred at 100 rpm. Placebo formulation (blank SEDDS, without drug) was also test-
ed simultaneously under identical conditions so as to check interference, if any. Aliquots
were collected periodically and replaced with fresh dissolution medium. Aliquots, after
filtration through Whatman filter paper (No. 41), were analyzed spectrophotometrically
at 238 nm for simvastatin content. The data was analyzed using the PCP Disso v 3.0 soft-
ware, India.
In vivo study in rats
The effect of formulation C (test formulation, TF) on plasma lipid profiles was de-
termined by comparison with reference formulation (RF, i.e., aqueous suspension con-
taining 1.7 mg mL–1 simvastatin, mean particle size 23 µm) and 2% (m/V) gum acacia as
a suspending agent) in healthy albino rats (Wistar strain) of either sex and weighing be-
tween 150–180 g. The study protocol was approved by the Institutional Animal Ethics
Committee of Poona College of Pharmacy, Pune, India. Animals had free access to food
and water. The animals were randomly divided into 4 treatment groups of 6 animals
each, viz., test treatment group (TTG), reference treatment group (RTG), placebo treat-
ment group (PTG) and control treatment group (CTG). The treatment was given for 21
days. Each treatment group received daily 1.5 mL of coconut oil orally in the morning
throughout 21 days. TTG, RTG and PTG additionally received formulation C (TF), aque-
ous suspensions of simvastatin (RF) and blank SEDDS, respectively. The administered
oral dose of TF and RF was 1.7 mg per animal once a day (equivalent to 10 mg kg–1 per
day). Blood samples were collected under light ether anesthesia by retro-orbital punc-
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ture at predetermined time intervals, viz., before treatment, and after 5, 10, 15 and 21
days in anticoagulated (EDTA-treated) glass vials. Plasma was separated by centrifuga-
tion at 3000 rpm for 25 min and stored frozen until further use.
Lipid profiling of plasma sample
Plasma samples were analyzed for total CH, HDL-CH and TG using in vitro diag-
nostic kits (Ensure Biotech, India). Briefly, fixed volumes of sample and standard were
mixed with the working reagent separately, followed by incubation at 37 °C for 10 min.
Absorbance of the developed color was read at 505 nm for CH and HDL-CH, and at 546
nm for TG determination. From the values of total CH, HDL-CH and TG, plasma very
low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) contents were deter-
mined from the above values (19).
Statistical analysis for the determination of differences in lipid profiles of treatment
and control groups was done by the unpaired t-test and ANOVA (significance level p <
0.05). The results were confirmed by Bonferroni’s multiple comparison as a post-hoc
test.
RESULTS AND DISCUSSION
Out of different oils screened for simvastatin solubilization, Lauroglycol showed the
highest solubility (around 90 mg mL–1) while Captex accommodated approximately 60
mg mL–1 of simvastatin. However, the systems developed with the former oil yielded
emulsions of moderate quality and the latter of very good quality, as observed visually.
To obtain the balance between solubility and emulsion quality, both of these oils were
mixed in a 1:1 (V/V) ratio and used as oil phase in further studies. Pseudo ternary phase
diagrams were constructed to determine the region of emulsion formation (data not
shown). Systems containing about 25–35% (m/m) Cr-EL yielded good quality emulsions.
At higher amounts of Captex (more than 40%, m/m), although the region of emulsifi-
cation increased, precipitation was observed in overnight storage under ambient condi-
tions.
Compositions of different formulations prepared with varying Cr-EL to Capmul ra-
tios are shown in Table I. All the prepared formulations were clear, isotropic solutions
with no signs of precipitation or separation. After 500-times dilution with water, formu-
lations A, B and C yielded good quality emulsions while D and E produced emulsions
of moderate and poor quality, respectively. Lack of surfactant in formulation E resulted
in a poor emulsion that readily broke, and was hence discarded. Turbidity of formula-
tion C (which was a clear and transparent system of slightly bluish color) was below the
limit of detection, probably due to very fine emulsion formed (Table II). Formulations A
and B showed low turbidity values (14.21 NTU and 12.95 NTU, respectively) owing to
the presence of adequate amounts of surfactant (Cremophor EL), wich primarily gov-
erns the resultant droplet size and its distribution. Oppositely, formulation D, with mode-
rate quality emulsion formation because of inadequate surfactant, showed very high
and variable turbidity (96.3 ± 15.2 NTU, mean ± SD, n = 3) due to coarser droplets, and
hence it was discarded.
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Droplet size analysis revealed the effect of varying amounts of Cr-EL and Capmul
in the formulated SEDDS (Table II). Formulation C with a 1:1 (V/V) ratio of Cr-EL to
Capmul showed the least mean droplet size, 124 nm (polydispersity index, 0.212). Chan-
ges in Cr-EL to Capmul ratios are most likely to alter the resultant HLB of the system
and the properties of liquid crystal (LC) interfaces. This in turn governs the size of drop-
lets formed (20). This is the appropriate choice of surfactant and cosurfactant together
with their proper concentrations, which provides an optimum self-emulsifying formula-
tion. The drug content varied for up to 3.9% between formulations A, B, and C, normaly,
ranged between 98.7 and 102.1 mg mL–1 (shown in Table II).
Conventional dissolution testing of SEDDS has a limitation in mimicking its real-
-time in vivo dissolution and such a technique can only provide a measure of disper-
sibility of SEDDS in the dissolution medium. Alternatively, for evaluating the in vitro
performance of SEDDS, drug diffusion studies using the dialysis technique are well docu-
mented in literature (14, 20, 21). In this study, diffusion profiles of all formulations did
not show any significant differences during initial 1 h, which might be the lag period.
However, at the end of 12 hours, formulation C showed about 82.2% diffusion against
69.3% and 48.9% from formulation B (simvastatin content 10.21 mg mL–1) and A (sim-
vastatin content 9.87 mg mL–1), respectively (Table III). This clearly indicates the effect
of mean droplet size on drug diffusion across dialyzing membrane. The amount of drug
diffused at time t, Qt, from the droplet to the aqueous environment can be given as:
Qt = f (1/r2K)
Thus, Qt is primarily a function of the radius of the droplet r and the partition coef-
ficient K (which indicates polarity of the drug) (7). Accordingly, formulation C, with the
least mean droplet size (124 nm) of all, offered very high surface area for drug partitioning,
which eventually equilibrated with the dialyzing medium. Similar observations have
been reported earlier (14). Based on these results, formulation C was chosen as a TF for
further in vivo studies in rats.
Bioavailability enhancement of simvastatin has been demonstrated in dogs with the
help of pharmacokinetic analysis (14). However, the primary site of action of simvastatin
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Table II. Evaluation of SEDDS formulationsa
Evaluation parameter
Formulation
A B C D
Turbidity (NTU) 14.21 ± 2.15 12.95 ± 2.06 BLDb 96.3 ± 15.24
Mean droplet size
(nm)d
414.42 ± 35.24 258.43 ± 26.51 124.86 ± 17.83 NDc
Drug found (mg mL–1) 98.7 ± 10.3 102.1 ± 8.9 101.2 ± 9.7 NDc
a Mean ± SD, n = 3.
b BLD – below limit of detection.
c ND – not done.
d PI – polydispersity index was less than 0.35 in all experiments.
is liver and oral bioavailability is less than 5% (17). Due to high intra- and inter-popula-
tion variations in liver metabolism patterns, plasma levels of simvastatin and its metabo-
lite (simvastatin acid) fluctuate to a large extent. Hence, high degrees of variations in
pharmacokinetic parameters of simvastatin and its active metabolite are often observed.
Alternatively, in vivo performance of simvastatin can be also evaluated using its phar-
macodynamic effects (17). Hypolipidemic activity of simvastatin causes reduction in ele-
vated total CH, LDL-CH and TG levels in blood. At the same time, it causes elevation of
plasma HDL-CH level, which promotes the removal of CH from peripheral cells and fa-
cilitate its delivery back to the liver. This pharmacodynamic effect is reported to be dose
dependent (22), and hence was used as a basis for the comparison of in vivo performance
of TF and RF. Administration of excess coconut oil, which is a rich source of saturated
fatty acids, promotes biosynthesis of cholesterol in liver and leads to hypercholesterol-
emia (23). The serum lipid profiles of all the experimental groups at different time inter-
vals are presented in Table IV. No significant differences were observed within or be-
tween four treatment groups for the three test parameters on day zero (initial) due to
random sampling of animals. After 5 days, in case of PTG and CTG, significant increases
(2 to 3-fold) in plasma CH, TG, VLDL and LDL levels were observed (p < 0.01); however,
HDL-CH levels were fairly unchanged. After the same period, significant changes in plas-
ma CH, TG, VLDL and LDL profiles were also observed for TTG and RTG (p < 0.05).
After 21 days of treatment with coconut oil (1.5 mL per day, orally), PTG and CTG
showed a marked increase in total CH (3.8-fold and 3.5-fold, respectively) and TG (3.2-
-fold and 2.8-fold, respectively) (p < 0.001). Particularly, in the case of CTG, a significant
increase in CH and TG, and VLDL and LDL levels (p < 0.001) and an insignificant in-
crease in HDL-CH from day zero to day 21 of the treatment indicated the inducement of
hypercholesterolemia due to administration of coconut oil. Similar findings were noted
for PTG. Lack of significant differences in the tested parameters for CTG and PTG after
the 21-day treatment inferred no appreciable effect of placebo components on the lipid
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Table III. Comparison of in vitro diffusion profiles of SEDDS formulationsa
Time (h)
Drug diffused (%)
Formulation A Formulation B Formulation C
0 0 0 0
1 7.4 ± 1.2 8.0 ± 2.5 9.5 ± 2.7
2 10.6 ± 1.6 12.6 ± 2.2 17.6 ± 3.1
4 25.6 ± 2.0 36.9 ± 2.6 41.2 ± 2.6
6 37.6 ± 2.1 54.9 ± 3.6 64.2 ± 3.2
8 42.3 ± 3.1 63.9 ± 4.6 75.5 ± 4.1
10 46.6 ± 2.6 67.5 ± 4.6 79.5 ± 3.2
12 48.9 ± 3.8 69.3 ± 3.5 82.2 ± 2.9
a Mean ± SD, n = 6.
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profiles of experimental animals. On the contrary, as expected, in TTG, the increase in
total CH and TG was much lower but significant (p < 0.001), while the RTG showed mar-
ginal increase (2.1-fold and 2.12-fold, respectively) (p < 0.001) in these parameters after
the 21-day treatment. Moreover, the increase in plasma HDL-CH (approximately 1.4-fold
for TTG and 0.7-fold for RTG) was remarkable (p < 0.001).
After the 21-day treatment, comparison of CTG against TTG and RTG revealed the
lipid-lowering effect of simvastatin. Plasma CH and TG levels were significantly lower
(0.25-fold and 0.35-fold, respectively) (p < 0.001) and HDL-CH levels were significantly
higher (2.2-fold, p < 0.001) in TTG compared to CTG. Also, plasma CH and TG levels
were significantly lower (0.46-fold and 0.59-fold, respectively) (p < 0.001) and HDL-CH
levels were significantly higher (1.75-fold, p < 0.001) in the case of RTG compared to
CTG.
Comparison of TTG against RTG, after the 21-day treatment, inferred the varying
lipid-lowering effects of simvastatin from TF and RF. Plasma CH and TG levels were sig-
nificantly lower (0.55-fold and 0.6-fold, respectively) (p < 0.001) and HDL-CH levels were
significantly higher (1.23-fold, p = 0.007) in TTG compared to RTG. Also, it is apparent
from Table IV that the changes in lipid levels from day zero to day 21 for TTG and RTG
are different. Comparison of changes took place in plasma lipid levels of TTG and RTG
groups after 21 days of study are shown in Table V. This clearly indicates the varying
lipid-lowering effects of simvastatin obtained by administering TF and RF.
Thus, TF showed a significantly better in vivo performance than RF in terms of phar-
macodynamic parameters. This observation is in accord with earlier reports (14, 17). En-
hanced pharmacodynamic performance of simvastatin formulated in SEDDS could be
ascribed to the combined effect of different mechanisms, like the presentation of drug in
solubilized form, large interfacial area made available for absorption, enhanced dissolu-
tion in the presence of surfactants, and increased cellular uptake of drug, probably due
to inhibition of cellular efflux systems (5, 7, 24).
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Table V. Comparison of TTG and RTG for pharmacodynamic parameters after 21 days of
studya
Test parameter
Increase in plasma level (%)
Ratio (TTG/RTG)
TTGb RTGc
CH 22.7 ± 2.5 105.6 ± 5.4 0.2
HDL-CH 142.5 ± 6.8 71.4 ± 4.6 2.0
TG 30.5 ± 2.6 115.0 ± 7.4 0.3
VLDL 29.9 ± 3.4 111.8 ± 4.6 0.3
LDL –82.6 ± 4.4d 114.6 ± 6.6 –
a Mean ± SD, n = 6.
b TTG – test treatment group.
c RTG – reference treatment group.
CONCLUSIONS
This study illustrated the potential of simvastatin SEDDS for oral administration.
Further studies are required to establish a correlation between pharmacokinetics and phar-
macodynamic responses of simvastatin when administered in the form of SEDDS.
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S A @ E T A K
Samoemulziraju}i pripravci za peroralnu primjenu simvastatina:
Ispitivanja in vitro i in vivo
PRADEEP PATIL, VANDANA PATIL i ANANT PARADKAR
Cilj rada bio je pripraviti samoemulziraju}i sustav za isporuku lijeka (SEDDS) za
simvastatin, hipolipemik koji se uz dijetu upotrebljava u terapiji hiperkolesterolemije i
dislipidemije. Simvastatin SEDDS su pripravljene koriste}i smjesu 1:1 (V/V) diestera kap-
rilne i kaprinske kiseline i poliglikoliziranih glicerida s razli~itim koncentracijama po-
lioksil 35 kastorovog ulja i C8/C10 mono-/diglicerida. Pripravcima su ispitana turbidi-
metrijska svojstva, veli~ina ~estica, udio lijeka i in vitro difuzijski profil. U pokusima in
vivo na {takorima pra}eni su parametri farmakodinami~kih markera kao {to su ukupni
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kolesterol u plazmi (CH), trigliceridi (TG) i lipoproteini velike gusto}e (HDL-CH) tije-
kom 21 dana. Pripravci koji sadr`e 9,1% (m/m) simvastatina i 23% (m/m) svake od po-
mo}nih tvari imaju najmanju prosje~nu veli~inu ~estica (124 nm) i iz njih je difuzija lijeka
optimalna. Ispitivani pripravci zna~ajno snizuju CH i TG u plazmi (5, odnosno 4 puta),
dok je koncentracija HDL-CH ostaje izrazito visoka, 2 puta vi{a u usporedbi s referent-
nom suspenzijom simvastatina poslije peroralne primjene tijekom 21 dan. Ispitivani pri-
pravci imaju bolji farmakodinami~ki profil u odnosu na referentni pripravak pa imaju
veliki potencijal za peroralnu primjenu simvastatina.
Klju~ne rije~i: simvastatin, SEDDS, farmakodinamika, peroralna primjena, lipidi u plazmi,
in vivo ispitivanja
Department of Pharmaceutics, Bharati Vidyapeeth Deemed University, Poona College of Pharmacy
Erandwane, Pune-411 038, Maharashtra State, India
Department of Environmental Sciences, University of Pune, Ganeshkhind, Pune-411 007
Maharashtra State
122
P. Patil et al.: Formulation of a self-emulsifying system for oral delivery of simvastatin: In vitro and in vivo evaluation, Acta Pharm. 57
(2007) 111–122.
